The startup develops a therapy utilizing antitumoral components and environment modulators derived from a newly identified human immune cell to treat glioblastoma multiforme, a highly aggressive brain tumor. This approach enables healthcare providers to delay tumor progression and extend patient survival through targeted treatment and detection of essential immune cells.
Funding
$280K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Glioblastoma multiforme is a highly aggressive brain tumor with limited effective treatment options, resulting in poor patient outcomes and a pressing need for innovative therapeutic approaches. Current treatments often fail to adequately address the complex tumor microenvironment and the tumor's ability to evade the immune system.
Solution
The startup is developing a novel therapy for glioblastoma multiforme that leverages antitumoral components and environment modulators derived from a newly identified human immune cell. This approach aims to target the tumor directly while also modulating the tumor microenvironment to enhance the body's natural immune response. By targeting both the tumor cells and the surrounding environment, the therapy seeks to delay tumor progression and extend patient survival. The therapy also incorporates methods for detecting essential immune cells, enabling personalized treatment strategies and improved monitoring of patient response.
Target Audience
The primary target audience includes healthcare providers specializing in oncology and neurology, as well as patients diagnosed with glioblastoma multiforme and their families.
Features
- Utilizes antitumoral components derived from a newly identified human immune cell.
- Employs environment modulators to disrupt the tumor microenvironment.
- Designed to target glioblastoma multiforme cells directly.
- Aims to enhance the body's natural immune response against the tumor.
- Includes methods for detecting essential immune cells for personalized treatment.